Bank of New York Mellon Corp cut its stake in Neogen Corporation (NASDAQ:NEOG – Free Report) by 3.7% in the first quarter, Holdings Channel.com reports. The firm owned 1,246,638 shares of the company’s stock after selling 47,640 shares during the period. Bank of New York Mellon Corp’s holdings in Neogen were worth $11,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. UMB Bank n.a. increased its position in shares of Neogen by 238.2% during the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock valued at $45,000 after purchasing an additional 4,523 shares during the period. Hantz Financial Services Inc. increased its holdings in Neogen by 816.9% in the 4th quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock valued at $53,000 after buying an additional 6,764 shares during the period. Cresset Asset Management LLC acquired a new position in shares of Neogen in the 2nd quarter valued at $53,000. Evergreen Capital Management LLC acquired a new position in shares of Neogen in the 2nd quarter valued at $56,000. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Neogen by 3,158.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company’s stock worth $58,000 after acquiring an additional 8,054 shares during the period. Institutional investors own 96.73% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on NEOG shares. Weiss Ratings lowered shares of Neogen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Wall Street Zen raised Neogen from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Neogen presently has a consensus rating of “Hold” and an average price target of $10.67.
Neogen Stock Performance
NASDAQ:NEOG opened at $12.04 on Friday. The stock has a market capitalization of $2.62 billion, a P/E ratio of -401.33, a price-to-earnings-growth ratio of 5.16 and a beta of 1.80. The company has a current ratio of 3.82, a quick ratio of 2.84 and a debt-to-equity ratio of 0.38. Neogen Corporation has a 1 year low of $4.56 and a 1 year high of $12.15. The firm has a 50 day moving average of $9.44 and a 200-day moving average of $9.62.
Neogen (NASDAQ:NEOG – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The firm had revenue of $225.30 million during the quarter, compared to analysts’ expectations of $212.35 million. During the same period last year, the firm posted ($2.82) EPS. The business’s revenue was down .1% on a year-over-year basis. As a group, sell-side analysts anticipate that Neogen Corporation will post 0.22 EPS for the current fiscal year.
Trending Headlines about Neogen
Here are the key news stories impacting Neogen this week:
- Positive Sentiment: Neogen reported fiscal Q4 adjusted earnings of $0.09 per share, above the $0.05 analyst consensus and substantially better than the $2.82-per-share loss reported in the year-ago quarter. Revenue of $225.3 million also exceeded estimates of $212.35 million. Neogen Beats Q4 Earnings and Revenue Estimates
- Positive Sentiment: Management forecast fiscal 2027 revenue of $880 million to $885 million, above the $851.1 million consensus estimate. First-quarter fiscal 2027 revenue guidance of $207 million to $209 million also topped the $204.9 million consensus. Neogen Fiscal 2027 Guidance
- Positive Sentiment: The company expects fiscal 2027 adjusted EBITDA of approximately $180 million to $182 million, signaling anticipated improvement in profitability and supporting the favorable investor reaction. Neogen Fiscal 2026 Results
- Neutral Sentiment: Despite the earnings beat, quarterly revenue was essentially flat year over year, down 0.1%, indicating that the stronger outlook depends on future growth rather than current top-line acceleration.
- Neutral Sentiment: Analysts’ average price target is approximately $10.67, below the stock’s recent trading level, suggesting valuation and expectations may limit additional upside. Analysts Set Neogen Price Target
- Negative Sentiment: Neogen plans to increase research and development spending by roughly 50% in fiscal 2027. Although intended to support longer-term growth, the investment could pressure near-term margins and earnings.
Neogen Company Profile
Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.
In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.
Featured Articles
- Five stocks we like better than Neogen
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Corporation (NASDAQ:NEOG – Free Report).
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.
